Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, ...

The following is a summary of “Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer,” published in the February 2025 ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

Mouth and throat cancers are highly treatable if caught early, but they are often diagnosed at later stages because people ...

Xinning Zhang and Ashley Maloney discovered that a geology technique shows promise in detecting cancer-like cells. If their ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.